Citations (7)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Clarisse Cazelles, Karim Belhadj, Hélène Vellemans, Vincent Camus, Elsa Poullot, Philippe Gaulard, Liana Veresezan, Emmanuel Itti, Stéphanie Becker, Muriel Carvalho, Jehan Dupuis, Fabien Le Bras, François Lemonnier, Louise Roulin, Taoufik El Gnaoui, Fabrice Jardin, Nicolas Mounier, Hervé Tilly & Corinne Haioun. (2021) Rituximab plus gemcitabine and oxaliplatin (R-GemOx) in refractory/relapsed diffuse large B-cell lymphoma: a real-life study in patients ineligible for autologous stem-cell transplantation. Leukemia & Lymphoma 62:9, pages 2161-2168.
Read now
Read now
Qi Guo, Yanmei Liu, Jiayuan Zhao, Jing Wang, Yue Li, Yunqing Pang, Jian Chen & Jing Wang. (2019) Evodiamine inactivates NF-κB and potentiates the antitumor effects of gemcitabine on tongue cancer both in vitro and in vivo. OncoTargets and Therapy 12, pages 257-267.
Read now
Read now
Mireia Franch-Sarto, Marc Sorigue, Laia López, Miriam Moreno, Josep-Maria Ribera & Juan-Manuel Sancho. (2019) Overall survival in patients with relapsed/refractory high grade B-cell lymphomas treated with gemcitabine, oxaliplatin with or without rituximab. Leukemia & Lymphoma 60:13, pages 3324-3326.
Read now
Read now
Articles from other publishers (4)
Georg Hess, Andreas Hüttmann, Mathias Witzens‐Harig, Martin H. Dreyling, Ulrich Keller, Reinhard Marks, Thomas Ernst, Christiane Pott, Andreas Viardot, Fabian Frontzek, Marcel Trautmann, Christian Ruckes, Oliver Deuster, Andreas Rosenwald, Matthias Theobald & Georg Lenz. (2022)
A phase
II
trial to evaluate the combination of pixantrone and obinutuzumab for patients with relapsed aggressive lymphoma: Final results of the prospective, multicentre
GOAL
trial
. British Journal of Haematology 198:3, pages 482-491.
Crossref
Crossref
Bertram Glass & Marie José Kersten. 2022. The EBMT/EHA CAR-T Cell Handbook. The EBMT/EHA CAR-T Cell Handbook
67
74
.
Monica Balzarotti, Massimo Magagnoli, Miguel Ángel Canales, Paolo Corradini, Carlos Grande, Juan-Manuel Sancho, Francesco Zaja, Anne-Marie Quinson, Valérie Belsack, Daniela Maier & Carmelo Carlo-Stella. (2021) A phase Ib, open-label, dose-escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma. Investigational New Drugs 39:4, pages 1028-1035.
Crossref
Crossref
Adam Buczkowski, Michał Gorzkiewicz, Artur Stepniak, Małgorzata Malinowska-Michalak, Paweł Tokarz, Paweł Urbaniak, Maksim Ionov, Barbara Klajnert-Maculewicz & Bartlomiej Palecz. (2020) Physicochemical and in vitro cytotoxicity studies of inclusion complex between gemcitabine and cucurbit[7]uril host. Bioorganic Chemistry 99, pages 103843.
Crossref
Crossref